TY - JOUR
T1 - Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's lymphoma
T2 - United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244
AU - Hoskin, Peter J.
AU - Lowry, Lisa
AU - Horwich, Alan
AU - Jack, Andrew
AU - Mead, Ben
AU - Hancock, Barry W.
AU - Smith, Paul
AU - Qian, Wendi
AU - Patrick, Philippa
AU - Popova, Bilyana
AU - Pettitt, Andrew
AU - Cunningham, David
AU - Pettengell, Ruth
AU - Sweetenham, John
AU - Linch, David
AU - Johnson, Peter W.M.
PY - 2009/11/10
Y1 - 2009/11/10
N2 - Purpose: This multicenter, prospective, randomized controlled trial compared the efficacy and toxicity of two chemotherapy regimens in advanced Hodgkin's lymphoma (HL): the weekly alternating Stanford V and the standard, twice-weekly regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Patients and Methods: Patients had stage IIB, III, or IV disease or had stages I to IIA disease with bulky disease or other adverse features. Radiotherapy was administered in both arms to sites of previous bulk (> 5 cm) and to splenic deposits, although this was omitted in the latter part of the trial for patients achieving complete remission (CR) in the ABVD arm. A total of 520 patients were randomly assigned and were assessed for the primary outcome measure of progression-free survival (PFS). Five hundred patients received protocol treatment, and radiotherapy was administered to 73% in the Stanford V arm and to 53% in the ABVD arm. Results: The overall response rates after completion of all treatment were 91% for Stanford V and 92% for ABVD. During a median follow-up of 4.3 years, there was no evidence of a difference in projected 5-year PFS and overall survival (OS) rates (76% and 90%, respectively, for ABVD; 74% and 92%, respectively, for Stanford V). More pulmonary toxicity was reported for ABVD, whereas other toxicities were more frequent with Stanford V. Conclusion: In a large, randomized trial, the efficacies of Stanford V and ABVD were comparable when given in combination with appropriate radiotherapy.
AB - Purpose: This multicenter, prospective, randomized controlled trial compared the efficacy and toxicity of two chemotherapy regimens in advanced Hodgkin's lymphoma (HL): the weekly alternating Stanford V and the standard, twice-weekly regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Patients and Methods: Patients had stage IIB, III, or IV disease or had stages I to IIA disease with bulky disease or other adverse features. Radiotherapy was administered in both arms to sites of previous bulk (> 5 cm) and to splenic deposits, although this was omitted in the latter part of the trial for patients achieving complete remission (CR) in the ABVD arm. A total of 520 patients were randomly assigned and were assessed for the primary outcome measure of progression-free survival (PFS). Five hundred patients received protocol treatment, and radiotherapy was administered to 73% in the Stanford V arm and to 53% in the ABVD arm. Results: The overall response rates after completion of all treatment were 91% for Stanford V and 92% for ABVD. During a median follow-up of 4.3 years, there was no evidence of a difference in projected 5-year PFS and overall survival (OS) rates (76% and 90%, respectively, for ABVD; 74% and 92%, respectively, for Stanford V). More pulmonary toxicity was reported for ABVD, whereas other toxicities were more frequent with Stanford V. Conclusion: In a large, randomized trial, the efficacies of Stanford V and ABVD were comparable when given in combination with appropriate radiotherapy.
UR - http://www.scopus.com/inward/record.url?scp=73949116794&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73949116794&partnerID=8YFLogxK
U2 - 10.1200/JCO.2009.23.3239
DO - 10.1200/JCO.2009.23.3239
M3 - Article
C2 - 19738111
AN - SCOPUS:73949116794
VL - 27
SP - 5390
EP - 5396
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 32
ER -